EA201400543A1 - Способы и композиции для чрескожной доставки - Google Patents

Способы и композиции для чрескожной доставки

Info

Publication number
EA201400543A1
EA201400543A1 EA201400543A EA201400543A EA201400543A1 EA 201400543 A1 EA201400543 A1 EA 201400543A1 EA 201400543 A EA201400543 A EA 201400543A EA 201400543 A EA201400543 A EA 201400543A EA 201400543 A1 EA201400543 A1 EA 201400543A1
Authority
EA
Eurasian Patent Office
Prior art keywords
progestin
methods
composition
disclosed
estrogen
Prior art date
Application number
EA201400543A
Other languages
English (en)
Other versions
EA026664B1 (ru
Inventor
Чарльз Г. Арнольд
Эйджис Кидониус
Томас М. Росси
Альфред Ф. Альтомари
Original Assignee
Эджайл Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эджайл Терапьютикс, Инк. filed Critical Эджайл Терапьютикс, Инк.
Publication of EA201400543A1 publication Critical patent/EA201400543A1/ru
Publication of EA026664B1 publication Critical patent/EA026664B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрывается композиция для чрескожной доставки прогестина для использования в гормональной терапии. Также раскрывается устройство для чрескожной доставки, содержащее данную композицию. Для применения в гормональной терапии только одного прогестина композиция содержит антиоксидант и не содержит эстроген. Для терапии с использованием прогестина и эстрогена композиция содержит прогестин, эстроген и дополнительный антиоксидант. Также раскрываются способы увеличения стабильности прогестинсодержащих композиций, включающих окисляющие агенты. Способы охватывают включение в композиции одного или более антиоксидантов.
EA201400543A 2011-11-04 2012-11-02 Композиция и устройство для трансдермальной доставки прогестина EA026664B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555546P 2011-11-04 2011-11-04
US201261645778P 2012-05-11 2012-05-11
PCT/US2012/063314 WO2013067346A1 (en) 2011-11-04 2012-11-02 Dermal delivery compositions and methods

Publications (2)

Publication Number Publication Date
EA201400543A1 true EA201400543A1 (ru) 2014-09-30
EA026664B1 EA026664B1 (ru) 2017-05-31

Family

ID=47278507

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400543A EA026664B1 (ru) 2011-11-04 2012-11-02 Композиция и устройство для трансдермальной доставки прогестина

Country Status (17)

Country Link
US (3) US9364487B2 (ru)
EP (1) EP2773333B1 (ru)
JP (1) JP6316749B2 (ru)
KR (1) KR20140088199A (ru)
CN (1) CN103957899A (ru)
AU (1) AU2012332254B2 (ru)
BR (1) BR112014010670A2 (ru)
CA (1) CA2854164C (ru)
EA (1) EA026664B1 (ru)
ES (1) ES2762460T3 (ru)
HK (1) HK1200317A1 (ru)
IL (1) IL232258A0 (ru)
IN (1) IN2014DN03247A (ru)
MX (1) MX353713B (ru)
PH (1) PH12014501000A1 (ru)
WO (1) WO2013067346A1 (ru)
ZA (1) ZA201402988B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
GB2521632B (en) * 2013-12-23 2020-12-16 Linscott Goode Steven Vermin control compositions
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
MX2020004491A (es) * 2017-10-30 2020-08-13 Kaken Pharma Co Ltd Preparacion externa para tratar tinea unguium.
JP7220473B2 (ja) * 2017-10-30 2023-02-10 帝國製薬株式会社 経皮投与製剤
CN112739383B (zh) * 2018-09-19 2024-03-15 埃斯普投资有限公司 过氧化物稳定的聚合物组合物及其制备方法和应用
CN113455506A (zh) * 2021-06-29 2021-10-01 无锡宏霸医疗科技有限公司 一种适用于日化产品的水相除臭去味剂及其制备方法
FR3125684A1 (fr) * 2021-07-28 2023-02-03 Roquette Freres Composition de dianhydrohexitols stables a l’oxydation et contenant un ester d’acide gallique
CN114259498B (zh) * 2021-12-02 2023-04-28 南通联亚药业股份有限公司 一种包含去氧孕烯和炔雌醇的药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
FR2739031B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
DE19700913C2 (de) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
GB9720470D0 (en) 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
WO2001001990A1 (en) * 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
BR0015802B1 (pt) * 1999-11-24 2014-04-29 Agile Therapeutics Inc Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
DE50115609D1 (de) * 2000-02-17 2010-10-14 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
JP4422430B2 (ja) * 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
WO2006036899A2 (en) * 2004-09-27 2006-04-06 Corium International, Inc. Transdermal systems for the delivery of estrogens and progestins
CA2604943C (en) * 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
AU2006249349B2 (en) * 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
DE102006050558B4 (de) * 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
TW200831139A (en) * 2006-11-29 2008-08-01 Wyeth Corp Estrogen/SERM and estrogen/progestin bi-layer tablets
US8246978B2 (en) 2007-07-10 2012-08-21 Agile Therapeutics, Inc. Dermal delivery device with reduced loss of its volatile components
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
WO2009009651A1 (en) 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with ultrasonic weld
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
EP2410859A4 (en) * 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION

Also Published As

Publication number Publication date
US20180325916A1 (en) 2018-11-15
EP2773333B1 (en) 2019-10-02
ZA201402988B (en) 2015-11-25
CA2854164C (en) 2021-04-13
IL232258A0 (en) 2014-06-30
WO2013067346A1 (en) 2013-05-10
KR20140088199A (ko) 2014-07-09
US20160250226A1 (en) 2016-09-01
MX2014005294A (es) 2014-09-22
BR112014010670A2 (pt) 2017-05-09
US9364487B2 (en) 2016-06-14
JP6316749B2 (ja) 2018-04-25
AU2012332254A1 (en) 2014-05-15
PH12014501000A1 (en) 2014-06-09
HK1201152A1 (en) 2015-08-28
HK1200317A1 (en) 2015-08-07
CN103957899A (zh) 2014-07-30
EA026664B1 (ru) 2017-05-31
CA2854164A1 (en) 2013-05-10
US20130116222A1 (en) 2013-05-09
JP2014532719A (ja) 2014-12-08
IN2014DN03247A (ru) 2015-05-22
AU2012332254B2 (en) 2017-06-22
EP2773333A1 (en) 2014-09-10
MX353713B (es) 2018-01-24
NZ624117A (en) 2016-02-26
ES2762460T3 (es) 2020-05-25

Similar Documents

Publication Publication Date Title
EA201400543A1 (ru) Способы и композиции для чрескожной доставки
MX2020013533A (es) Formulaciones y terapias de reemplazo de combinacion de hormonas naturales.
MX365818B (es) Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
CR20110553A (es) Terapia complementaria contra el cáncer
PY1337526A (es) Métodos para tratar o prevenir asma administrando un antagonista de IL-4R.
BR112014031824A2 (pt) terapias de reposição hormonal transdérmica
PH12015502161A1 (en) Therapeutic compounds and compositions
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
GB201200062D0 (en) Estradiol oromucosal liquid compositions
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
WO2014146111A3 (en) Analgesic compounds and methods of use
UA112746C2 (uk) Протиракові стероїдні лактони, ненасичені в положенні 7(8)
MX2014008693A (es) Administracion transdermica de hormonas.
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
PH12015501538A1 (en) Topical ocular analgesic agents
GEP201606586B (en) Pediatric oral liquid compositions containing nepadutant
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
NZ738063A (en) Stable povidone-iodine compositions
Xin-Hua et al. How to Ensure the Education Budget Accounted for 4% of GDP
吴波 Who is Disgusting

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU